What is known about the safety and efficacy of using different technologies for the first and second doses of COVID vaccines?
What is known about the safety and efficacy of using different technologies for the first and second doses of COVID vaccines?
This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.
This article has been translated from its original language. Please reach out if you have any feedback on the translation.
SciLine reaches out to our network of scientific experts and poses commonly asked questions about newsworthy topics. Reporters can use these responses in news stories, with attribution to the expert.
SciLine reaches out to our network of scientific experts and poses commonly asked questions about newsworthy topics. Reporters can use these responses in news stories, with attribution to the expert.
Publication
What our experts say
Context and background
Resources
Expert Comments:
Dave O’Connor, PhD
I'm not sure there are good answers, at least not right now. This new data represents some of the first experimental evidence for ‘real world’ vaccine mixing in a controlled setting. There are lots of anecdotal reports - for example, I received two doses of the AstraZeneca vaccine as part of the US Phase III clinical trial, but nonetheless received a full course of Moderna as the AstraZeneca vaccine has not been approved in the US. And I was pretty reactogenic after the first Moderna vaccine with fever, malaise, and injection site tenderness, none of which I experienced after my AstraZeneca vaccination.
